Al-Toubah T, Strosberg J, Halfdanarson T, et al. - Researchers evaluated alterations in symptoms as well as pulmonary function tests (PFTs) in response to somatostatin analog (SSA) treatment in patients who received a clinical and/or pathologic diagnosis of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) and had chronic respiratory symptoms. They examined 42 patients. Of those, 33 had symptomatic improvement. In addition, an improvement in FEV1 post-treatment was evident in 14 of 15 patients in whom PFTs were checked. Overall, the ability of SSA treatment in improving chronic respiratory symptoms and PFTs was evident in patients with DIPNECH.